IDH2 and acute myeloid leukemia: Furthermore, the compensatory activation of the PI3K-AKT and RAS–RAF-MAPK pathways have emerged as a plausible route of resistance in AML treated with TKIs such as inhibitors of FLT3, BCL2, and IDH [39].